Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24925830 | 1.00 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1CYP3A4ALOX15MAOA | |
| SCHEMBL2405377 | 1.00 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1CYP3A4ALOX15MAOA | |
| SCHEMBL7681064 | 1.00 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1CYP3A4ALOX15MAOA | |
| SCHEMBL7687609 | 0.98 | MAOA (0.52) | SIGMAR1ALDH1A1CYP3A4ALOX15MAOA | |
| SCHEMBL386561 | 0.91 | SIGMAR1 (0.48) | SIGMAR1ALDH1A1ALOX15MAOAMIF | |
| Bromide SCHEMBL28242863 | 0.89 | SIGMAR1 (0.46) | SIGMAR1MAOAMIFMAOB | |
| SCHEMBL17934738 | 0.84 | ALDH1A1 (0.42) | SIGMAR1ALDH1A1CYP3A4ALOX15NAAA | |
| SCHEMBL17934733 | 0.84 | ALDH1A1 (0.42) | SIGMAR1ALDH1A1CYP3A4ALOX15NAAA | |
| SCHEMBL17934741 | 0.84 | ALDH1A1 (0.42) | SIGMAR1ALDH1A1CYP3A4ALOX15NAAA | |
| SCHEMBL103124 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CYP3A4ALOX15MAOAMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883746-B2 | α-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient | SNU R&DB FOUNDATION (KR) | 2014-11-11 | — | — | US | disclosed |
| US-20100104590-A1 | ALPHA-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2010-04-29 | — | — | US | disclosed |
| EP-2102225-A1 | ALPHA-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | SNU R&DB Foundation (KR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008082156-A1 | ALPHA-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104590-A1 | ALPHA-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GALC, GBA1, IL4 | SIGMAR1 2242/4885ALDH1A1 1750/4885CYP3A4 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.